OpenProtein.AI Launches No-Code Platform to Democratize AI-Driven Protein Design for Biologists
MIT spinout's open-source models let researchers design proteins without writing a single line of code.
OpenProtein.AI, a company founded by MIT alumni Tristan Bepler and former professor Tim Lu, has launched a no-code platform designed to democratize access to advanced AI for protein engineering. The platform provides biologists and researchers, particularly those without machine learning expertise, with a suite of open-source foundation models and tools. These tools enable tasks like designing novel proteins, predicting protein structure and function, and training custom models, all through an intuitive interface that requires no coding. The company is already deploying its technology with researchers across pharmaceutical and biotech companies of all sizes, while offering the platform for free to academic scientists.
The core technology stems from Bepler's PhD work at MIT, where he developed one of the first generative AI 'protein language models' to understand the relationships between a protein's amino acid sequence and its function. The platform aims to bypass the traditional need to predict protein structure entirely, going straight from sequence to functional design. This approach can significantly shorten development cycles for new therapeutics and industrial enzymes. The founders envision creating a broader 'language for describing biological systems' and are exploring applications beyond proteins to other biological modalities.
- No-code platform provides open-source AI foundation models for protein design and analysis, eliminating the coding barrier for biologists.
- Founded by MIT's Tristan Bepler and Tim Lu, leveraging early research into protein language models that predict function from sequence.
- Free for academic use and deployed in biotech/pharma to accelerate therapeutic development by making cutting-edge AI accessible.
Why It Matters
Democratizes powerful AI for drug discovery, letting biologists directly design novel proteins to accelerate new therapeutics.